Related Experiment Video

Updated: May 25, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment

Wolfram Brugger1, Michael Thomas

  • 1Medical Center II, Department of Hematology/Oncology, Schwarzwald-Baar Clinic, Academic Teaching Hospital University of Freiburg, Villingen-Schwenningen, Germany. wolfram.brugger@sbk-vs.de

Lung Cancer (Amsterdam, Netherlands)
|January 28, 2012
PubMed

Insights

Receptor-tyrosine kinase inhibitors (TKIs) offer initial success in advanced non-small cell lung cancer (NSCLC) but resistance develops. Irreversible TKIs and combination therapies show promise for overcoming acquired resistance to epidermal growth factor receptor (EGFR) TKIs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Advanced non-small cell lung cancer (NSCLC) treatment has improved with receptor-tyrosine kinase inhibitors (TKIs).
  • Epidermal growth factor receptor (EGFR) is a key target for TKIs, especially in patients with activating mutations.
  • Acquired resistance to EGFR-TKIs like gefitinib and erlotinib limits long-term efficacy.

Purpose of the Study:

  • To review current strategies for overcoming secondary resistance to EGFR-TKIs in NSCLC.
  • To evaluate the potential of novel therapeutic approaches in preclinical and clinical settings.

Main Methods:

  • Analysis of data from phase II/III clinical trials.
  • Review of preclinical and clinical evidence for irreversible TKIs and combination therapies.
  • Examination of multi-kinase inhibition and vertical inhibition strategies.

Main Results:

  • Single-agent EGFR-TKIs provide only temporary success due to acquired resistance.
  • Irreversible TKIs (e.g., afatinib, PF00299804) demonstrate potential in overcoming resistance.
  • Combined approaches, including dual EGFR/MET inhibition and antibody-drug conjugates, are emerging strategies.

Conclusions:

  • Overcoming secondary EGFR-TKI resistance in NSCLC requires novel therapeutic strategies.
  • Irreversible TKIs and combination therapies represent promising future directions for managing advanced NSCLC.
  • Future research should focus on validating these approaches to improve patient survival outcomes.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...